Join Experts and Patients in NYC for a Day of Learning and Connecting Register Free Today
Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Learn more about this revolutionary cancer treatment.
Understand the Basics
Find clinical trials that match your diagnosis, stage and treatment history.
Meet the CRI scientists committed to the development of immunotherapy.
Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy combinations and the promise of several novel immunotherapies, including anti-IDO1 checkpoint blockade and a personalized, patient-specific vaccine. Other measures of immunotherapy’s effectiveness, such as patient quality of life, were also discussed. Below are some of the most important findings that were revealed today:
Multiple Tumor Types:
Head and Neck Cancer:
Melanoma / Skin Cancers:
Stomach & Gastrointestinal Cancer:
ASCO17: Day 2 Immunotherapy Highlights
Read Previous Article
ASCO17: Days 4 and 5 Immunotherapy Highlights
Read Next Article
*Immunotherapy results may vary from patient to patient.
National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006
(800) 992-2623(212) 832-9376Staff Directory
Biomarkers will be crucial to taking advantage of combination immunotherapy’s full potential
Nivolumab becomes second checkpoint immunotherapy approved for colorectal cancer